Retatrutide phase 3 results show 28.3% average weight loss at 12 mg over 80 weeks

Eli Lilly reports that participants taking 12 mg of retatrutide lost an average of 70.3 pounds (28.3%) over 80 weeks in its phase 3 obesity trial. The company also reports reductions in knee osteoarthritis pain and obstructive sleep apnea severity. In a separate type 2 diabetes trial, it says average A1C reductions reached up to 2.0% at 40 weeks. Nausea, diarrhea and vomiting were among the most common adverse events. Retatrutide remains investigational and is legally available only to trial participants.